C-squared Pharma

Activities: Ingredients
C-squared Pharma

Trending Articles

  1. Loftware and RiseNow partner to strengthen supply chain traceability and compliance in healthcare settings The alliance pairs Loftware's SAP-integrated product identification platform with RiseNow's procurement and supply chain advisory services, delivering end-to-end...
  2. AlzeCure receives $12m upfront as NeuroRestore Alzheimer's platform licensing deal with QuantumCell closes The payment — comprising $7m in licence fees and $5m direct investment — kicks off a collaboration worth more than $2.2bn in potential milestones, with QuantumCell assuming...
  3. University of Birmingham develops "switchable smart gel" that could revolutionise targeted drug delivery The multi-responsive material switches between gel and liquid states under UV light or acid exposure, with acid-triggered release mechanisms offering a potential platform for...
  4. As new CTO, Christian Reichardt is driving the technological advancement of Optima Pharma This investment is driven by growth areas such as biologics, GLP-1 products, and other sterile pharmaceuticals, as well as the increasing demand for isolator and high-potency...
  5. SCHOTT Pharma advances climate action with updated science-based climate targets Updated Scope 3 emissions target strengthens focus on measurably reducing emissions across the value chain

Upcoming event

CPhI Milan

6–8 October 2026 | Exhibition | Fiera Milano, Italy See all

Related Content

Manufacturing
C2 PHARMA receives CEP approval for Oxybuprocaine hydrochloride

C2 PHARMA receives CEP approval for Oxybuprocaine hydrochloride

C2 PHARMA proudly announces the approval of a Certificate of Suitability (CEP) for Oxybuprocaine hydrochloride by the European Directorate for the Quality of Medicines and Health Care (EDQM)
Manufacturing
C2 PHARMA marks 10 years at CPHI Milan with expanded ophthalmic APIs

C2 PHARMA marks 10 years at CPHI Milan with expanded ophthalmic APIs

The complany is ready to showcase its expanding ophthalmic API portfolio and global regulatory filings, featuring Naphazoline Hydrochloride and Tropicamide
Ingredients
C2 PHARMA expands ophthalmic API portfolio with Naphazoline Hydrochloride launch

C2 PHARMA expands ophthalmic API portfolio with Naphazoline Hydrochloride launch

C2 PHARMA, the global leader in ophthalmic and niche active pharmaceutical ingredients (APIs), proudly announces the launch of its latest API, Naphazoline Hydrochloride
Regulatory
C2 Pharma's Tropicamide receives CEP from the European Directorate

C2 Pharma's Tropicamide receives CEP from the European Directorate

The CEP approval of the ophthalmic drug allows C2 Pharma to distribute Tropicamide globally
Ingredients
C2 PHARMA announces upcoming launch of new oxybuprocaine hydrochloride API

C2 PHARMA announces upcoming launch of new oxybuprocaine hydrochloride API

C2 PHARMA excited to announce the upcoming launch of its new API, oxybuprocaine HCL, an ingredient that will be manufactured by manufacturing partner Laurus Labs
Ingredients
C2 Pharma to participate in DCAT Week 2024

C2 Pharma to participate in DCAT Week 2024

The C2 PHARMA team will be located in the Benjamin hotel in Suite 2202
Ingredients
C2 PHARMA receives DMF approval in China for pilocarpine nitrate

C2 PHARMA receives DMF approval in China for pilocarpine nitrate

C2 PHARMA announces the approval of a C-DMF for pilocarpine nitrate — granted on 30 October 2023 — an API manufactured by our Brazilian partner Anidro do Brasil
Subscribe now